NASDAQ:ADMA

ADMA Biologics (ADMA) Stock Forecast, Price & News

$4.06

0.00 (0.00%)

(As of 06/7/2023 ET)

Compare

Today's Range: $4.00
▼
$4.10
50-Day Range: $3.12
▼
$4.22
52-Week Range: $1.85
▼
$4.30

Volume: 1.54 million shs
Average Volume: 2.37 million shs
Market Capitalization: $902.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.25

ADMA Biologics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 29.3% Upside
$5.25 Price Target
Short Interest: Bearish
5.03% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.14
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.09) to $0.07 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

560th out of 981 stocks

Biological Products, Except Diagnostic Industry

88th out of 159 stocks

3.5

Analyst's Opinion

Consensus Rating
ADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.25, ADMA Biologics has a forecasted upside of 29.3% from its current price of $4.06.
Amount of Analyst Coverage
ADMA Biologics has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.03% of the outstanding shares of ADMA Biologics have been sold short.
Short Interest Ratio / Days to Cover
ADMA Biologics has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in ADMA Biologics has recently decreased by 1.24%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
ADMA Biologics does not currently pay a dividend.
Dividend Growth
ADMA Biologics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADMA.

2.1

News and Social Media Coverage

News Sentiment
ADMA Biologics has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for ADMA Biologics this week, compared to 3 articles on an average week.
Search Interest
32 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 1,500% compared to the previous 30 days.
MarketBeat Follows
5 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ADMA Biologics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.90% of the stock of ADMA Biologics is held by insiders.
Percentage Held by Institutions
71.17% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ADMA Biologics are expected to grow in the coming year, from ($0.09) to $0.07 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ADMA Biologics is -16.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ADMA Biologics is -16.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ADMA Biologics has a P/B Ratio of 5.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Stock News Headlines

June 5, 2023 | finance.yahoo.com

Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study

June 5, 2023 | finance.yahoo.com

BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody

June 8, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

June 2, 2023 | americanbankingnews.com

ADMA Biologics (NASDAQ:ADMA) Lowered to Sell at StockNews.com

June 1, 2023 | msn.com

Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design

May 30, 2023 | finance.yahoo.com

Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval

May 29, 2023 | finance.yahoo.com

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

May 26, 2023 | finance.yahoo.com

Plasma Derived Therapies Global Market to 2027: Increasing Prevalence of Genetic Disorders Drives Growth

June 8, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 25, 2023 | finance.yahoo.com

Immutep (IMMP) Up on Initial Data From Lung Cancer Study

May 22, 2023 | finance.yahoo.com

Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%

May 19, 2023 | americanbankingnews.com

ADMA Biologics (NASDAQ:ADMA) Coverage Initiated by Analysts at StockNews.com

May 17, 2023 | finance.yahoo.com

ADMA Biologics (NASDAQ:ADMA) rallies 18% this week, taking one-year gains to 102%

May 16, 2023 | americanbankingnews.com

ADMA Biologics, Inc. (NASDAQ:ADMA) to Post Q2 2023 Earnings of ($0.02) Per Share, HC Wainwright Forecasts

May 13, 2023 | americanbankingnews.com

ADMA Biologics (NASDAQ:ADMA) Shares Gap Up to $3.57

May 13, 2023 | americanbankingnews.com

Traders Purchase High Volume of Call Options on ADMA Biologics (NASDAQ:ADMA)

May 12, 2023 | finance.yahoo.com

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

May 11, 2023 | finanznachrichten.de

ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023 | marketwatch.com

10-Q: ADMA BIOLOGICS, INC.

May 11, 2023 | finance.yahoo.com

Q1 2023 ADMA Biologics Inc Earnings Call

May 10, 2023 | finance.yahoo.com

ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update

May 9, 2023 | americanbankingnews.com

ADMA Biologics (ADMA) Scheduled to Post Quarterly Earnings on Wednesday

May 4, 2023 | americanbankingnews.com

ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

May 3, 2023 | finance.yahoo.com

ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023

May 2, 2023 | finance.yahoo.com

ADMA Biologics Announces Amendment to Credit Agreement

April 30, 2023 | americanbankingnews.com

ADMA Biologics (NASDAQ:ADMA) Stock Price Crosses Below Two Hundred Day Moving Average of $3.31

April 28, 2023 | marketwatch.com

Plasma Therapeutics Market Size By 2030

See More Headlines

ADMA Price History

30 days | 90 days | 365 days | Advanced Chart

ADMA Company Calendar

Last Earnings: 3/23/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ADMA
CUSIP: N/A
CIK: 1368514
Web: www.admabiologics.com
Phone: (201) 478-5552
Fax: 201-478-5553
Employees: 527
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.25
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $4.50
Forecasted Upside/Downside: +29.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,900,000.00
Net Margins: -26.22%
Pretax Margin: -26.22%
Return on Equity: -37.22%
Return on Assets: -14.82%

Debt

Debt-to-Equity Ratio: 1.06
Current Ratio: 7.19
Quick Ratio: 2.73

Sales & Book Value

Annual Sales: $181.89 million
Price / Sales: 4.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.69 per share
Price / Book: 5.88

Miscellaneous

Outstanding Shares: 222,273,000
Free Float: 209,159,000
Market Cap: $902.43 million
Optionable: Optionable
Beta: 0.90

Key Executives

Adam S. Grossman
President, Chief Executive Officer & Director

Atkinson Vernon
Operations Director

Brian Lenz
Chief Financial Officer & Executive Vice President

Kaitlin Kestenberg
Vice President-Compliance & Clinical Operations

Lucy DeMario
Senior Director-Scientific & Data Analysis

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ADMA Stock - Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings or view top-rated stocks.
What is ADMA Biologics' stock price forecast for 2023?: 2 brokerages have issued 12-month price targets for ADMA Biologics' shares. Their ADMA share price forecasts range from $4.50 to $6.00. On average, they anticipate the company's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price.
View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts.
How have ADMA shares performed in 2023?: ADMA Biologics' stock was trading at $3.88 at the start of the year. Since then, ADMA stock has increased by 4.6% and is now trading at $4.06.
View the best growth stocks for 2023 here.
When is ADMA Biologics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ADMA earnings forecast.
How were ADMA Biologics' earnings last quarter?: ADMA Biologics, Inc. (NASDAQ:ADMA) issued its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The biotechnology company earned $49.98 million during the quarter, compared to the consensus estimate of $49.02 million. ADMA Biologics had a negative net margin of 26.22% and a negative trailing twelve-month return on equity of 37.22%. During the same period in the prior year, the business earned ($0.09) EPS.
What ETFs hold ADMA Biologics' stock?: ETFs with the largest weight of ADMA Biologics (NASDAQ:ADMA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Inspire Fidelis Multi Factor ETF (FDLS), Invesco Raymond James SB-1 Equity ETF (RYJ), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Vanguard U.S. Momentum Factor ETF (VFMO).
What guidance has ADMA Biologics issued on next quarter's earnings?: ADMA Biologics updated its FY 2025 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $300.00M-.
What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?: 9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).
What is ADMA Biologics' stock symbol?: ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
Who are ADMA Biologics' major shareholders?: ADMA Biologics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.38%), State Street Corp (5.85%), Stonepine Capital Management LLC (3.45%), Assenagon Asset Management S.A. (3.00%), Geode Capital Management LLC (1.82%) and Two Sigma Investments LP (1.04%). Insiders that own company stock include Adam S Grossman, Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Perceptive Advisors Llc and Young Kwon.
View institutional ownership trends.
How do I buy shares of ADMA Biologics?: Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ADMA Biologics' stock price today?: One share of ADMA stock can currently be purchased for approximately $4.06.
How much money does ADMA Biologics make?: ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $902.43 million and generates $181.89 million in revenue each year. The biotechnology company earns $-65,900,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.
How many employees does ADMA Biologics have?: The company employs 527 workers across the globe.
How can I contact ADMA Biologics?: ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for the company is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553.

This page (NASDAQ:ADMA) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial